immunomedics reports second quarter 2020 results

Submit Demands Online

2020/8/5The Company will host a conference call and live audio webcast with supporting slides today at 5:00 p m Eastern Time to discuss second quarter 2020 financial results and provide a corporate update To access the conference call please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 9887775 2020/8/11Recently in News on August 5 2020 Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update Encouraging early adoption of Trodelvy in U S with $20 1M net sales in first two months of launch You can read further details here

Immunomedics Reports First Quarter 2020 Results and

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update Stocks: IMMU release date:May 06 2020 Trodelvy received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy

Conference Call The Company will host a conference call and live audio webcast with supporting slides today at 5:00 p m Eastern Time to discuss second quarter 2020 financial results and provide a corporate update To access the conference call please dial (877

2020/7/27MORRIS PLAINS N J July 27 2020 (GLOBE NEWSWIRE) -- Immunomedics Inc (NASDAQ: IMMU) ("Immunomedics" or the "Company") a leading biopharmaceutical company in the area of antibody-drug conjugates today announced that it will host a conference call on Wednesday August 5 2020 at 5:00 p m Eastern Time to discuss financial results for the second quarter of 2020

2020/7/27MORRIS PLAINS N J July 27 2020 (GLOBE NEWSWIRE) -- Immunomedics Inc (NASDAQ: IMMU) ("Immunomedics" or the "Company") a leading biopharmaceutical company in the area of antibody-drug conjugates today announced that it will host a conference call on Wednesday August 5 2020 at 5:00 p m Eastern Time to discuss financial results for the second quarter of 2020

GeoPark Limited (GeoPark or the Company) (NYSE: GPRK) a leading independent Latin American oil and gas explorer operator and consolidator with operations and growth platforms in Colombia Peru Argentina Brazil Chile and Ecuador reports its

Immunomedics Appoints Michael Pehl President and

Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Updat GL 07/27 Immunomedics to Report Second Quarter 2020 Results and Host Conference Call a GL More news Financials (USD) Sales 2020 120 M--Net income 2020-263 M

MORRIS PLAINS N J Feb 27 2020 (GLOBE NEWSWIRE) -- Immunomedics Inc ("Immunomedics" or the "Company") a leading biopharmaceutical company in the area of antibody-drug conjugates today reported financial results for the fourth quarter and

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update Trodelvy received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch

Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update GlobeNewswire Inc - 8/5/2020 4:00:10 PM Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5 2020 Dow Jones

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update Stocks: IMMU release date:May 06 2020 Trodelvy received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy

2020/8/5The Company will host a conference call and live audio webcast with supporting slides today at 5:00 p m Eastern Time to discuss second quarter 2020 financial results and provide a corporate update To access the conference call please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 9887775

2020/8/5Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update - read this article along with other careers information tips and advice on BioSpace Encouraging early adoption of Trodelvy in U S with $20 1M net sales in first two months of launch

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update Trodelvy received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch

Immunomedics to Report Second Quarter 2020 Results

2020/7/27MORRIS PLAINS N J July 27 2020 (GLOBE NEWSWIRE) -- Immunomedics Inc (NASDAQ: IMMU) ("Immunomedics" or the "Company") a leading biopharmaceutical company in the area of antibody-drug conjugates today announced that it will host a conference call on Wednesday August 5 2020 at 5:00 p m Eastern Time to discuss financial results for the second quarter of 2020

Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Updat GL 07/27 Immunomedics to Report Second Quarter 2020 Results and Host Conference Call a GL 07/27 AstraZeneca bets up to $6 billion on new Daiichi cancer drug RE RE

ASCENT study stopped early due to compelling evidence of efficacy across multiple endpoints topline results around mid-2020 Morris Plains N J May 6 2020 — Immunomedics Inc (NASDAQ: IMMU) ("Immunomedics" or the "Company") a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) today reported financial results for the first quarter of 2020

Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update - read this article along with other careers information tips and advice on BioSpace Trodelvy received accelerated approval from FDA for third-line metastatic triple-negative breast cancer

2020/8/5Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update - read this article along with other careers information tips and advice on BioSpace Encouraging early adoption of Trodelvy in U S with $20 1M net sales in first two months of launch

ASCENT study stopped early due to compelling evidence of efficacy across multiple endpoints topline results around mid-2020 MORRIS PLAINS N J May 06 2020 (GLOBE NEWSWIRE) -- Immunomedics Inc ( IMMU ) ("Immunomedics" or the "Company") a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC) today reported financial results for the first quarter of 2020